Clinical Research

Advarra IRB experts discuss unique issues that research involving emerging infectious diseases like coronavirus can raise for IRB review. Read more:

Advarra VP of Insitutional Services James Riddle discusses using virtual trial components in traditional study designs. Read more:

Advarra Director of Biosafety Daniel Eisenman reviews opportunities, risks, and risk mitigation strategies for coronavirus research. Read more:

The Revised Common Rule is here after multiple delays, exceptions, and many training sessions. As of January 20, 2020, this regulation is in full effect.

Go beyond the regulatory requirements and examine three key actions research organizations must consider before conducting planned emergency research.

What did the research community enjoy most in 2019? Read Advarra's most popular blogs from industry experts and IRB members here.

Reportable events can be tricky: according to the regulations, not every unanticipated event should be submitted to the IRB.

Understand how the new HUD guidance clarifies responsibilites of the IRB and institutions, while widening the access of small communities to HUDs.

Social media has emerged as a valuable tool for diverse stakeholders across the research community. Learn about the risks and benefits in this article.

Learn how institutions attract more studies from the the tale of two sites: one with an integrated research administration, and one without.

Participant compensation is often a complicated matter. This blog will shed light on what an IRB considers during its review.

Study-specific screening consent is a subtype of informed consent, which ensures a research participant understands of the research and its risks.